An intensive search for genetic disorders that could underlie amyotrophic lateral sclerosis (ALS) has uncovered pathogenetic variants in about 10% of sporadic ALS (SALS) and 60% of familial ALS (FALS) patients[@b1]. While this represents remarkable progress in only a few years, a major question is whether most SALS arises from environmental factors, genetic predisposition, or some combination of the two. Attempts have been made to look for environmental factors or gene-environment interactions underlying ALS in, for example, pesticide exposure[@b2], but despite work from many research groups no convincing environmental factor for ALS has been found. Furthermore, numerous genome-wide association studies (GWAS) have revealed no reproducible findings of common variants that would lead to ALS susceptibility in a substantial proportion of patients[@b3]. There could be a number of reasons for such negative results in GWAS, one being a mismatch of exposure to environmental factors and the presence of susceptibility genes. While there may be an environmental contribution to SALS, the genetic contribution could come mostly from rare variants, which still allows for strong gene-environment interactions.

If SALS has a strong genetic component, consideration needs to be given to the genetic mechanisms that could be responsible for the sporadic occurrence of most cases of ALS. One form of inheritance that can give rise to an apparently sporadic condition, especially in small families, is that of recessive variants[@b4]. Homozygous variants in ALS have already been described in *SOD1*, *OPTN*, and *FUS*[@b1], and other rare variants could be responsible to further SALS cases[@b4]. Recessive inheritance due to rare compound heterozygous variants is another genetic mechanism that can give rise to a sporadic disorder, since both rare variants are unlikely to be reproduced in the next generation. It has often been pointed out that with the demographic shift to smaller families, a disease with a recessive inheritance or with a low penetrance will seem sporadic in a large number of cases[@b5].

*De novo* mutation, in which the pathogenetic variant arises for the first time in the offspring of normal parents, is a further mechanism that can give rise to an apparently sporadic disorder. *De novo* mutations in *FUS*[@b6], *ERBB4*[@b7] and *ATXN2*[@b8] have previously been suggested to be associated with ALS.

A powerful method of looking for recessive and *de novo* variants underlying a sporadic disorder is the use of case-unaffected-parents trios. Large numbers of these trios are difficult to collect in ALS, since it is unusual to have access to living parents of ALS patients, with the average age of disease onset being in the early 60 s. In 2011, a genome-wide copy number analysis of 12 SALS trios found a number of *de novo* copy number variants (CNVs) in the SALS offspring; 11 of these CNVs involved genes, some of which were in pathways suspected in the pathogenesis of ALS[@b9]. More recently, exome sequencing of 47 SALS trios brought to light *de novo* single nucleotide variants in genes that may be involved in the pathogenesis of ALS[@b10].

In an attempt to uncover rare recessive and *de novo* variants that could underlie SALS, we therefore sequenced the exomes of 44 Australian case-unaffected-parents trios.

Results
=======

ALS offspring patients and unaffected parents
---------------------------------------------

White blood cell DNA samples were available from 44 trios (see [Table 1](#t1){ref-type="table"} for the number of recessive and de novo variants found in each ALS patient, and [Supplementary Table S1](#s1){ref-type="supplementary-material"} online for further clinical details of the patients and all ages). Thirty-seven of the offspring had classical sporadic ALS (SALS) with upper and lower motor neuron signs, three had sporadic progressive muscular atrophy (SPMA), two had sporadic progressive bulbar palsy (SPBP), one had sporadic primary lateral sclerosis (SPLS), and one had sporadic frontotemporal degeneration with motor neuron disease (SFTD-MND).

The average age of disease onset of our ALS trio (ALS^TRIO^) offspring was 46.1 y (SD 9.1 y, range 26--63 y). In comparison, the average age of disease onset for the 828 SALS patients in the Australian MND DNA Bank was 61.9 y (SD 11.5 y, range 26--99 y), a significant difference on unpaired two-tailed t-testing (p \< 0.0001).

The average age of fathers at the birth of ALS^TRIO^ offspring was 29.4 y (SD 5.1 y, range 22--42 y) and that of the 689 Australian MND Bank fathers at ALS offspring birth was 31.4 y (SD 6.9 y, range 15--67 y), a non-significant difference on t-testing (p = 0.06). The average age of mothers at the birth of ALS^TRIO^ offspring was 26.3 y (SD 4.0 y, range 20--38) and that of the 689 Australian MND Bank mothers at ALS offspring birth was 28.2 y (SD 6.1 y, range 13--50 y), also a non-significant difference on t-testing (p = 0.05).

Total numbers of variants
-------------------------

The whole exomes of the 44 trios were sequenced to an average of 52.5X coverage (see Methods and [Supplementary Methods](#s1){ref-type="supplementary-material"} online for sequencing details). A total of 307,780 variants passed false-positive and site filters, and 305,622 variants passed Hardy-Weinberg Equilibrium tests (p \< 0.0001). An average of 55,727 variants per individual was found (which included a 500 bp wingspan from the target space that added an additional 200 kbp of non-coding space with off-target variant calling). Transition/Transversion (Ts/Tv) ratios for coding and non-coding bases per individual (to assess the accuracy of single nucleotide variant filtering), and replacement to silent ratios per individual (to infer the direction and magnitude of natural selection acting on protein coding genes), are available online in [Supplementary Tables 2 and 3](#s1){ref-type="supplementary-material"}, respectively.

Homozygous and compound heterozygote recessive variants
-------------------------------------------------------

The carrier rate of a potential recessive allele is estimated to be approximately 1% based on an incidence of 2 per 100,000 per year. Out of 16,866 unique autosomal recessive loss of function and nonsynonymous variants, 90 were at global minor allele frequency (MAF) \< 1%. Out of 125,006 loss of function and nonsynonymous compound heterozygous, 5,008 were at global MAF \< 1%. For these calculations, we required that the transmitted allele in both parents was MAF \< 1%. After rigorous filtering based on global MAF, predicted functional consequence, and sequence conservation (for pathways see [Figure 1](#f1){ref-type="fig"}), 49 recessive and compound heterozygous variants remained for validation and further analysis. Full lists of the coding recessive and compound heterozygous variants detected are shown in [Supplementary Dataset 1](#s1){ref-type="supplementary-material"} and [Supplementary Dataset 2](#s1){ref-type="supplementary-material"} respectively online. We validated 28 compound heterozygous variants in 19 different genes ([Table 2](#t2){ref-type="table"}), which involved 12 (27%) ALS^TRIO^ patients ([Table 1](#t1){ref-type="table"}). In 6 (14%) ALS^TRIO^ patients 9 homozygous recessive variants in 9 different genes were found ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}). The deleterious nature of these recessive variants can be judged from their average SIFT score of 0.0058 and average PolyPhen2 score of 0.0008. A quarter of the genes with these recessive variants have significantly increased expression in the spinal cord compared to non-central nervous system tissues[@b11] ([Table 2](#t2){ref-type="table"}).

*De novo* variants
------------------

Eighty-one *de novo* variants passed manual review in IGV and 54 were validated with Sanger sequencing ([Figure 1](#f1){ref-type="fig"}). See [Supplementary Table S4](#s1){ref-type="supplementary-material"} online for the complete list of *de novo* variants. Seventeen of the *de novo* variants were coding, involving 12 (27%) ALS^TRIO^ patients ([Tables 1](#t1){ref-type="table"} and [3](#t3){ref-type="table"}). Of these 17 variants, 15 were missense (10 identified as deleterious or damaging using SIFT, PolyPhen and Condel), one splice site, and one nonsense. Twenty-four percent of the genes in which we found *de novo* variants have significantly increased expression in the spinal cord compared to non-central nervous system tissues[@b11] ([Table 3](#t3){ref-type="table"}). Although two coding *de novo* variants were found in five ALS^TRIO^ patients, the distribution of *de novo* variants followed a Poisson distribution (see [Supplementary Fig. S1](#s1){ref-type="supplementary-material"} online), indicating that multiple *de novo* alleles in any one individual are unlikely to contribute to ALS risk.

Relation of variants found to known ALS variants
------------------------------------------------

The frequency of variants in ALS susceptibility genes and the frequency of known ALS susceptibility variants were assessed in our cohort using ALSoD[@b12]. No increased burden of coding variants in known ALS genes was found in this cohort. All of the coding variants have been previously identified, and the alternate allele frequencies of these variants are similar to those in the NHLBI ESP and the 1000 Genomes Project, with the exception of a few non-synonymous variants that had elevated frequencies (see [Supplementary Table S5](#s1){ref-type="supplementary-material"} for a list of these). Given our limited sample size, however, we were unable to determine whether this enrichment was statistically significant.

Homozygous segments
-------------------

No statistically significant enrichment of homozygous segments was found by size, burden, or genomic location in ALS^TRIO^ patients versus controls.

Functional implications
-----------------------

All except one (*HENMT1*) of the recessive variants were accepted in the DAVID functional annotation analysis. This analysis revealed an enrichment of genes sharing the domain-1 of dynein heavy chain (*DNAH10*, *DNAH2* and *DNAH9*) (p = 0.00006, FDR = 0.004). In addition, the above three genes, along with *ABCA2* and *ATP8B3* (all five genes with ATPase activity and an ATPase-associated domain) were enriched (p = 0.0023, FDR = 0.058). The above five variants also have nucleotide binding capacity, together with *CNGA4*, *MYO3B* and *RAB25* (p = 0.0025, FDR = 0.07). Therefore of these eight genes, all have nucleotide binding capacity, five have ATPase activity, and three have dynein heavy chain domain-1 activity.

Among the 17 genes with *de novo* non-synonymous or splicing variants, *METTL22* was not present in the DAVID identification list and was excluded from the analysis. Within the remaining 16 genes, seven (*LIMD1*, *FOXN3*, *GTF2H4*, *MLL3*, *STK36*, *SND1* and *TRRAP*) are related to regulation of transcription (p \< 0.02, FDR \< 0.1). Another enriched group, comprising *ANAPC7*, *FOXN3* and *PSMB7*, is involved in cell cycle processes (p \< 0.05, FDR \< 0.1).

Our DAVID analyses showed no involvement in any functional pathways of genes containing either recessive or *de novo* variants. The previous ALS trio exome study of Chesi et al., on the other hand, which used the same DAVID analysis, reported that chromatin regulator genes were significantly enriched[@b10]. When we combined our and the Chesi et al. *de novo* variants, and submitted them to functional annotation analysis, genes related to transcription regulation became more significantly enriched than our previous analysis (p = 0.000032, FDR = 0.0018). These 15 enriched genes comprised six from our ALS^TRIO^ list (*LIMD1, FOXN3, GTF2H4, MLL3, SND1* and *TRRAP*) and nine from the Chesi et al. list (*CNOT1, ELL, FOXA1, FOXK1, HDAC10, SRCAP, SS18L1, ZNF410, ZNF778*). This combined analysis therefore gives further weight to the suggestion that disturbances by *de novo* variants of transcription regulation genes may be a pathogenetic mechanism in ALS. On the other hand, genes related to chromatin modification were not significant in the combined *de novo* analysis, with a high false discovery rate (FDR = 0.27).

Discussion
==========

Due to the late age of onset of ALS, and the possibility of incomplete penetrance, it is difficult to assess whether SALS is truly sporadic. For example, multiple system atrophy was once thought to be sporadic, but recently-identified compound heterozygous and recessive mutations in *COQ2* segregate with the disease, and heterozygous mutations in the same gene predispose individuals to this disease[@b13]. Additionally, it has been reported that ALS patients harbour a greater number of rare homozygous segments than controls, and that these segments are longer and contain more genes[@b4]. This suggested further evidence for a recessive cause for apparently sporadic ALS, though our finding of no excess homozygosity in ALS patients does not support this hypothesis of long runs of homozygosity containing rare ALS susceptibility variants. This does not necessarily mean that recessive inheritance can be ruled out, just that long runs of homozygosity were not found in our cohort.

With our dataset of case-parent trios we tested the hypothesis that rare, recessive-acting variants could contribute to disease susceptibility. Indeed, a number of promising candidate genes with recessive or compound heterozygous variants were identified. For example, in one family we identified two extremely rare variants in *ABCA2* that are highly conserved and are predicted to be damaging. *ABCA2* encodes an ATP-binding cassette transporter and plays a role in intracellular sterol trafficking. It is highly expressed in the brain and regulates low-density lipoprotein metabolism in neuronal cells[@b14]. Dysregulation of *ABCA2* is associated with amyloid beta deposition in Alzheimer\'s disease[@b15], and *ABCA2* null mice accumulate more gangliosides and sphingomyelin in neuronal tissue compared to wild-type mice[@b16].

We identified a recessive variant in *RAB25* in one ALS^TRIO^ patient. This gene encodes a protein involved in membrane trafficking and has nucleotide binding capacity. A meta-analysis of genome-wide association studies showed that a common variant at the *SYT11*/*RAB25* locus is associated with Parkinson\'s disease in Caucasians[@b17], suggesting a role for this gene in neurodegenerative diseases.

*CACNA1H* encodes a protein in the voltage-dependent calcium channel complex, and we identified two extremely rare damaging variants inherited as a compound heterozygote in one ALS^TRIO^ patient. Dysregulation of calcium homeostasis in spinal and motor neurons has been previously demonstrated in mouse models of ALS[@b18]. This leads to altered excitability of motor neurons with modified synaptic activity and neuronal excitotoxicity[@b19]. Of interest, in presymptomatic ALS patients cortical hyperexcitability appears to be an early feature[@b20]. Our results give more weight to the idea that variants in voltage-dependent calcium channel genes play a role in ALS susceptibility.

Functional annotation analysis of the recessive variants showed enrichment for genes that are involved in the dynein heavy chain (*DNAH10*, *DNAH2* and *DNAH9*). This is of interest since defects in axonal transport have long been suspected to play a part in ALS[@b21]. A group of five genes, comprising the three dynein-related genes above, as well as *ABCA2* and *ATP8B3,* were enriched for ATPase activity. Na,K-ATPase has been suggested to be involved in mutant-*SOD1* ALS[@b22], but data on the activity of other forms of APTase in ALS are sparse, despite the fact that altered energy metabolism is a possible mechanism in ALS[@b23]. Finally, the above five genes, as well as a further three (*CNGA4*, *MYO3B* and *RAB25*) are enriched for nucleotide binding activity. Of note, caution needs to be exercised in attributing importance to the variants in *DNAH10* and *MYO3B* since exome sequencing frequently finds variants in these genes[@b24].

Recent studies of individual SALS patients and their parents have identified *de novo* variants in ALS-associated genes such as *FUS*[@b25] and *CREST*[@b26]. Other sporadic disorders such as autism spectrum disorder demonstrate a similar pattern of recurrent *de novo* variants[@b27]. Interestingly, we identified a novel *de novo* initiator codon variant in *CHRM1*, a gene that also harbored a *de novo* missense variant in a previous ALS exome trio study[@b10]. This gene encodes a cholinergic receptor and is predicted to be involved in diseases of motor neurons and frontotemporal dementia, which is related to ALS. *CHRM1* is predominantly expressed in the parasympathetic nervous system and influences the effects of acetylcholine in the central and peripheral nervous systems. In patients with Alzheimer\'s disease, loss of *CHRM1* exacerbates cognitive decline[@b28] and increases amyloid pathology[@b29]. In spinal cord injuries significantly reduced gene expression of muscarinic cholinergic receptors intensifies motor dysfunction[@b30]. Our results further support the hypothesis that damaging variants in *CHRM1* contribute to neurodegenerative disorders such as ALS.

Of note, *CHRM1* was the only gene in which *de novo* variants (in different regions of the gene) were found in both our and the previous ALS trio exome study of Chesi et al.[@b10], with the two studies containing a total of 91 ALS patients. This implies that, if *de novo* mutations do play a major part in ALS, large numbers of private mutations in different genes are likely to be responsible for the disease.

We identified a novel coding *de novo* variant in *ITPR2*. Common variations in this gene have been associated with ALS, with the expression of *ITPR2* being increased in the peripheral blood of ALS patients[@b31]. *ITPR2* is highly expressed in motor neurons where it encodes a calcium channel on the endoplasmic reticulum, the latter a site a great interest in ALS[@b32]. Dysfunction of *ITPR2* with increased intracellular calcium may lead to motor neuron cell death[@b31] and overexpression of murine *ITPR2* in the *SOD1*^G93A^ ALS mouse model damages cells by increasing the release of neuronal calcium[@b33]. In neuronal cell lines, oxidative stress leads to calcium dysregulation by upregulating *ITPR2* expression, which increases calcium release into the nucleus[@b34]. The association of *ITPR2* with ALS has not been replicated in other genome-wide association[@b35] or single nucleotide variant studies, though these only assayed common, and not rare, variants. Our results, on the other hand, suggest that rare variants in this gene may contribute to the pathogenesis of ALS.

Functional annotation analysis of our *de novo* variants showed seven that are related to transcription regulation (*LIMD1*, *FOXN3*, *GTF2H4*, *MLL3*, *STK36*, *SND1* and *TRRAP*), which is in keeping with the findings of abnormal RNA transcription and processing in ALS[@b36]. Caution though needs to be exercised attributing significance to the *de novo* variant found in *STK36* since this gene frequently contains variants in exome sequencing[@b24]. The finding of *de novo* variants in three genes related to the cell cycle (*ANAPC7*, *FOXN3* and *PSMB7*) is in accord with suggestions that cell cycle abnormalities underlie some instances of ALS[@b37].

It has been suggested that ALS may be caused by variants in a number of genes within one individual, the so-called oligogenic hypothesis[@b38]. Our findings support this hypothesis, since nine ALS^TRIO^ patients had more than one gene with either a recessive or *de novo* rare variant. The Poisson distribution for novel *de novo* coding variants in our study suggests that these variants alone are unlikely to be involved in an oligogenic process. However, 75% of our ALS patients who had *de novo* variants had concurrent recessive or other *de novo* variants; only 3 patients had a single *de novo* variant, and in these it is quite possible that other recessive or *de novo* variants outside of the exome sequencing targets could play contributory roles.

Although evidence for an oligogenic mechanism for ALS was present in our present study, we looked only at single nucleotide variants. Other genetic abnormalities, such as copy number variants, DNA methylation[@b39], or somatic mutations[@b40] could interact with the variants we found in our ALS^TRIO^ patients to confer further susceptibility to disease. For example, when 12 of the present ALS^TRIO^ patients had genome-wide CNVs analysed with microarrays in a previous study[@b40], *de novo* CNVs were found in 11 of them ([Table 1](#t1){ref-type="table"}). CNVs that overlapped with genes or promoters were found in eight of these patients, including three with multiple CNVs.

ALS trio studies are uncommon, and without access to parent DNA we do not know how many mutation-carrying parents of ALS patients never develop the disease, or develop it at a much older age than their offspring. ALS-associated variants were found in our study in four ALS^TRIO^ patients as well as in an unaffected parent; one of these was in *SOD1*, two in *C9orf72*, and one in *TDP-43*[@b41]. Either environmental or modifying genetic variations could be responsible for this difference in phenotype between parent and offspring. Unaffected mutation-bearing parents could also carry a protective genetic variant elsewhere in their genomes. Our finding that all four of the above ALS^TRIO^ patients had additional single nucleotide or copy number variants suggests that other genetic variants may be needed for the ALS phenotype to appear in some patients who have apparently single gene mutations.

Limitations of the present study are: (1) Our ALS patients had a younger average age of onset that is usual for this disease, so they could represent a different subgroup where genetic variants are more common than in most sporadic ALS. (2) A parent could present with the onset of ALS much later in life (a not uncommon clinical scenario), so we cannot be sure that the ALS in our trios was truly of an isolated/sporadic nature. (3) We did not analyse the whole genome, so potentially significant recessive or *de novo* variants in intronic or intergenic regions could not be detected. (4) Further assessment of compound heterozygote and *de novo* variant frequency in ALS will only be able to be undertaken once larger numbers of ALS trios become available, which will require an international collaborative effort. A number of groups are presently undertaking exome sequencing on large numbers of individual ALS patients, so whether the variants we found are truly private mutations or are more common will soon be known. Not having parental DNA, however, means these studies will not be able to determine whether the variants are actually recessive or *de novo* in nature. (5) Exome capture is inherently biased towards the creation of false positives. For this reason we imposed several quality control steps in an attempt to filter out false positives. For the *de novo* variants we used Polymutt software that takes into account the parental genotypes when calling a *de novo* variant in the offspring. Of the variants that did not validate, 14 were due to poor Sanger data quality in one or both of the parents and four were due to poor Sanger data quality in the offspring. Seven variants were actually homozygous reference in the child and two variants were present (but undercalled from exome data) in the parents, representing true false positives. Although there are slightly more *de novo* variants than would be expected from a true exome (\<1 per family), most of these were non-coding or silent mutations. There were only 17 coding (15 missense) *de novo* variants out of the 44 families; this number is in line with *de novo* coding events in other exome studies[@b42]. (6) Because of our relatively small number of trios, we did not have sufficient numbers to undertake a rare variant transmission disequilibrium test (TDT) that would yield adequate statistical power[@b43][@b44].

As is common in other genomics-based studies, we expect that the variants we found will be a springboard for other researchers to develop model systems to further explore their functionality. We consider all our 28 recessive and 17 *de novo* variants to be strong candidates for a role in ALS, since our vigorous *in silico* analyses ensured that we reported only validated variants that are rare and involved in processes or metabolic pathways implicated in ALS. Complex model systems will be needed to test the functionality of these variants, since testing has to take into account the probability that multiple variants are acting together, and that exposure to environmental toxins, such as heavy metals[@b45] and neurotoxic amino acids[@b46], are also playing a part in the disease. Future studies using a combination of whole genome nucleotide sequences, structural variations, and epigenetic differences, using multiple tissues to look for somatic mutations, and obtaining DNA from multiple generations, are likely to be needed to uncover all the variants comprising the genetic contribution to sporadic ALS.

In conclusion, our exome sequencing of ALS-unaffected-parents trios has uncovered rare homozygous, compound heterozygous, and *de novo* variants that are likely to play a role in the pathogenesis of this disease. Most of these appear to be private variations, which implies that we will be unlikely to find any more mutations (such as those in *C9orf72*) that are common to large numbers of sporadic ALS patients. The implications of this study are four-fold: firstly, there are no previously published ALS trio exome studies showing the widespread occurrence of potentially deleterious compound heterozygous variants. Secondly, only one previous ALS trio study has demonstrated *de novo* variants, and our study confirmed these do occur, though in different genes (apart from one shared between the two studies), indicating that most are likely to be rare or private variants. Thirdly, we validated extremely rare, highly conserved, deleterious recessive mutations in our sporadic ALS patients. Hidden recessive inheritance in ALS has been hypothesised for many years, and we have now been able to show the importance of this mode of inheritance that could explain the sporadic nature of some ALS, possibly in combination with other recessive or *de novo* variants. Finally, our findings give the best evidence so far that oligogenic variants underlie much of sporadic ALS.

Methods
=======

Ethics statement
----------------

The study protocol was approved by the Sydney South West Area Health Service Human Research Ethics Committee. Informed written consent was obtained from each individual for their DNA to be used for research purposes. All methods were carried out in accordance with the approved guidelines and regulations.

SALS patients and unaffected parents
------------------------------------

Individuals selected for study were patients with ALS who had donated blood samples to the Australian Motor Neuron Disease DNA Bank, and whose ALS-unaffected parents had also given blood samples to the Bank. The diagnosis of ALS was made by a neurologist using standard criteria. For the purpose of this study, patients were considered to have "sporadic" ALS if they had no history of ALS in any family member at the time of blood sampling, even if an ALS-associated mutation was found in that patient and their family member. All ALS offspring in this study are referred to as "ALS Trio" (ALS^TRIO^) patients.

Exome sequencing
----------------

For details of exome sequencing see [Supplementary Methods](#s1){ref-type="supplementary-material"} online, and for sequencing metrics see [Supplementary Table S6](#s1){ref-type="supplementary-material"} online.

Variant calling and annotation pipelines
----------------------------------------

[Figure 1](#f1){ref-type="fig"} outlines the methods used to filter the exome variant calls to detect autosomal recessive, compound heterozygous, and *de novo* variants in the ALS offspring of the trios. For details of variant calling and annotation pipelines see [Supplementary Methods](#s1){ref-type="supplementary-material"} online.

Validation of variants
----------------------

For details of the method to validate the variants see [Supplementary Methods](#s1){ref-type="supplementary-material"} online.

ALSoD analysis
--------------

Data from the ALS online database (<http://alsod.iop.kcl.ac.uk/>) were downloaded, and variant calls from the exomes were intersected with the previously identified ALS susceptibility variants. The affected and unaffected carrier frequencies were calculated using GEMINI, a framework for exploring genome variation.

Homozygous segments
-------------------

Thirty of 44 ALS probands were genotyped on the Illumina Human Omni Express Bead Chip. Control data were drawn from the 379 European descent 1000 Genomes individuals that were genotyped on the Illumina Omni 2.5 Bead Chip. Data for both sets were imported into the whole genome analysis tool PLINK (v.1.07)[@b47] and standard quality control procedures were applied. Samples were excluded if they had call rates \<95%, single nucleotide polymorphisms (SNPs) with minor allele frequencies \< 0.01, Hardy-Weinberg equilibrium p-values \< 0.0001, or non-random missingness in cases versus controls. The two datasets were combined and the intersection of the two marker lists was used for a total of 667,708 SNPs genome-wide. SNPs were pruned based on linkage disequilibrium using a "light" pruning scheme[@b48], where SNPs with r^2^ \> 0.9 in a 50 SNP window were removed, leaving 307,288 SNPs. In addition, none of the cases were outliers from the 1000 Genomes European ancestry populations based on PLINK multidimensional scaling analysis. Runs of homozygosity (segments \>2 Mb) were identified from the autosomal chromosomes in PLINK[@b4] and burden and association analyses were performed as previously described[@b4], with the exception that the gene list was taken from the UCSC Table Browser hg19 RefSeq genes. Briefly, homozygous segments were coded as copy number variants and analyzed using the PLINK rare copy number variant burden and association analysis. p-values were generated from 100,000 case/control permutations and statistical significance was set at a genome-wide corrected p-value \< 0.05.

Functional implications
-----------------------

To predict the functional implications of the identified variants, lists of *de novo* and recessive variants were generated from the exome sequencing data and submitted to the Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7)[@b49]. The NimbleGen SeqCap EZ Human Exome gene list was used as a background. Potential functional enrichments and pathway analysis were explored, with p-values \< 0.05 and false discovery rates \< 0.1 selected as significant. Pathway analysis was also undertaken on the combined *de novo* variant findings in our and in the Chesi et al. ALS trio exome study[@b10].

Author Contributions
====================

K.M.S. performed the variant calling, analysed the exome sequencing data with IVA and GEMINI, performed the ALSoD and homozygosity analyses and co-drafted the article. B.Y. performed functional annotation analyses and assisted in data analysis and writing the article. D.K. assisted in data analysis and writing the article. E.M. contributed to study design, writing the article and gave final approval for publication of Washington University School of Medicine data. R.P. conceived the study, supplied DNA samples and clinical information, contributed to the study design, co-drafted the article, and gave final approval for publication of University of Sydney data.

Additional Information
======================

**Accession codes:** All appropriate datasets are available in the database of Genotypes and Phenotypes (dbGaP) (accession number phs000831).

Supplementary Material {#s1}
======================

###### Supplementary Information

Supplementary Information

###### Supplementary Information

Dataset 1

###### Supplementary Information

Dataset 2

We thank ALS patients and their parents for donating DNA samples, treating neurologists for supplying clinical information, MND Associations in all Australian states for assisting with sample collections, and the Production and Apipe groups at The Genome Institute for their contributions to this study. Prof Ronald Trent provided laboratory facilities and critically reviewed the manuscript, Dr Pak Leng Cheong undertook *C9orf72* mutation testing, Mr Stephen Kum Jew provided technical assistance, and Ms Joanne Nelson assisted with dbGaP submission. Supported by an Australian National Health and Medical Research Council project grant \#1032443 and a Motor Neuron Disease Research Institute of Australia grant-in-aid. Blood DNA samples were obtained from the Australian Motor Neuron Disease DNA Bank which is supported by an Australian National Health and Research Council Enabling Grant \#402703.

![Filtering schema for exome variant calls in case-unaffected parents trios.\
(1) To identify autosomal recessive and compound heterozygous variants (left track), variants were called using the unique union of VarScan and SAMtools calls. The trio was phased using BEAGLE v4 software and annotated using the NCBI single nucleotide polymorphism database (dbSNP) and Variant Effect Predictor (VEP). Ingenuity variant analysis (IVA) and Genome Mining (GEMINI) software were then used to rigorously filter variants based on quality, minor allele frequency, deleteriousness, inheritance patterns, conservation and involvement in motor neuron pathways (see [Supplementary Methods](#s1){ref-type="supplementary-material"} for parameters). The unique union of these variants was manually reviewed and independently validated using Sanger sequencing. (2) To identify *de novo* variants (right track), variants were called using Polymutt, a pedigree-aware variant caller. Phasing and annotation were as per the autosomal recessive and compound heterozygous variants. Variants were then filtered and manually reviewed to eliminate systematic false positives. The remaining variants were validated with Sanger sequencing.](srep09124-f1){#f1}

###### Clinical details and numbers of recessive and *de novo* variants detected in ALS trio patients

  Trio ID    Gender   Diagnosis   Age at onset   Homozygous variants   Compound heterozygous variants   De novo variants   De novo CNVs (previous study)   ALS mutation
  --------- -------- ----------- -------------- --------------------- -------------------------------- ------------------ ------------------------------- --------------
  \#01        Male       ALS           44                                                                                                                        
  \#02       Female      ALS           49                                                                      2                         2                       
  \#03       Female      ALS           35                                                                                                3                       
  \#04       Female      ALS           26                                                                                                4                       
  \#05       Female      ALS           50                                            1                                                   4                       
  \#06        Male       ALS           36                                                                                                3                  C9orf72 F
  \#07        Male       ALS           36                                                                                                3                       
  \#08       Female      PMA           51                                                                      2                         3                       
  \#09        Male       ALS           53                                                                                                4                       
  \#10        Male       ALS           44                                                                      1                         3                       
  \#11       Female      ALS           53                                            1                                                   3                       
  \#12       Female      PBP           58                 1                                                                              4                       
  \#13        Male       ALS           53                 1                                                                             na                       
  \#14        Male       ALS           27                                            2                         1                        na                       
  \#15        Male       ALS           35                                            1                                                  na                    SOD1 F
  \#16        Male     FTDMND          58                                            1                                                  na                       
  \#17        Male       ALS           51                                                                                               na                       
  \#18       Female      ALS           47                                                                                               na                       
  \#19        Male       ALS           53                                            1                                                  na                   TDP-43 M
  \#20        Male       ALS           56                 4                                                    1                        na                       
  \#21        Male       ALS           45                                                                      1                        na                       
  \#22        Male       ALS           46                 1                                                                             na                       
  \#23        Male       ALS           44                                            1                                                  na                       
  \#24        Male       ALS           36                                            2                         2                        na                       
  \#25       Female      ALS           42                                                                                               na                       
  \#26        Male       ALS           41                                            1                                                  na                       
  \#27        Male       ALS           47                                                                                               na                       
  \#28        Male       PMA           55                                                                                               na                       
  \#29       Female      PBP           55                                                                                               na                       
  \#30        Male       ALS           50                 1                                                    2                        na                       
  \#31       Female      ALS           53                                                                                               na                       
  \#32        Male       ALS           57                                                                                               na                       
  \#33        Male       ALS           42                                                                                               na                       
  \#34        Male       ALS           48                                                                                               na                       
  \#35        Male       ALS           46                                                                      2                        na                  C9orf72 F
  \#36        Male       ALS           59                                            1                                                  na                       
  \#37        Male       ALS           28                                                                                               na                       
  \#38       Female      ALS           45                                                                                               na                       
  \#39       Female      ALS           53                 1                                                                             na                       
  \#40       Female      ALS           63                                                                                               na                       
  \#41        Male       ALS           37                                            1                         1                        na                       
  \#42        Male       ALS           30                                            1                         1                        na                       
  \#43       Female      PLS           45                                                                      1                        na                       
  \#44        Male       ALS           46                                                                                               na                       

The ALS trio patients had a younger average age than usual for ALS. Most patients had classical ALS. Included in the table are *de novo* CNVs from 12 of the patients that were found in a previous study[@b9]. Four ALS trio patients who had known ALS-associated mutations also had recessive or *de novo* variants. CNV: copy number variant. F: mutation also found in father, M: mutation also found in mother, na: not applicable.

###### Recessive homozygous or compound heterozygous variants in ALS trio patients

  Gene         Trio ID   Chrom   Position    Recessive inheritance     Impact      Amino acid change   Minor allele frequency ESP   Minor allele frequency 1KG   dbSNP 137 rsID    Spinal cord differential expression
  ----------- --------- ------- ----------- ----------------------- ------------- ------------------- ---------------------------- ---------------------------- ---------------- ----------------------------------------
  ABCA2         \#24       9     139908464          Cpd Het           Missense          V1422F                  0.008303                       0.01               rs147917446       Up[\*\*\*](#t2-fn1){ref-type="fn"}
  ABCA2         \#24       9     139916347          Cpd Het           Missense           M224K                     NR                           NR                     NR          Up[\*\*\*\*](#t2-fn1){ref-type="fn"}
  ATP8B3        \#16      19      1788909           Cpd Het           Missense          G1019D                  0.003602                        0                 rs202137046        Down[\*](#t2-fn1){ref-type="fn"}
  ATP8B3        \#16      19      1796751           Cpd Het           Missense           C524Y                     NR                           NR                     NR            Down[\*](#t2-fn1){ref-type="fn"}
  CACNA1H       \#14      16      1265267           Cpd Het           Missense          V1683M                     NR                           NR                     NR           Down[\*\*](#t2-fn1){ref-type="fn"}
  CACNA1H       \#14      16      1265315           Cpd Het           Missense          A1699T                  0.006668                      0.0041              rs148651456       Down[\*\*](#t2-fn1){ref-type="fn"}
  CNGA4         \#24      11      6261613           Cpd Het           Missense           G197R                     NR                           NR                     NR                           ND
  CNGA4         \#24      11      6261718           Cpd Het           Missense           V232M                     NR                           NR                     NR                           ND
  DENND2C       \#20       1     115130508        Homozygous          Missense       Y833H; Y776H               0.004075                      0.0023               rs61753528       Down[\*\*](#t2-fn1){ref-type="fn"}
  DNAH10        \#23      12     124323006          Cpd Het           Missense          M1518V                  0.009286                      0.0027              rs145483216        Up[\*\*](#t2-fn1){ref-type="fn"}
  DNAH10        \#23      12     124409693          Cpd Het           Missense          R3837C                  0.002361                      0.0027              rs144421774        Up[\*\*](#t2-fn1){ref-type="fn"}
  DNAH2         \#41      17      7727209           Cpd Het           Missense          R3757H                     NR                           NR                     NR                           ND
  DNAH2         \#41      17      7734055           Cpd Het           Missense          G4003V                     NR                           NR                     NR                           ND
  DNAH9         \#26      17     11775004           Cpd Het           Missense          L1963F                     NR                           NR                     NR                           ND
  DNAH9         \#26      17     11840674           Cpd Het           Missense          I2671M                  0.001307                        NR                rs143953217                       ND
  EIF4E1B       \#20       5     176072210        Homozygous          Missense           R147H                  0.003643                      0.0023              rs115365515      Up[\*\*\*\*](#t2-fn1){ref-type="fn"}
  GORASP1       \#19       3     39140352           Cpd Het           Missense           D162Y                  0.00692                        0.01                rs13886448       Up[\*\*\*](#t2-fn1){ref-type="fn"}
  GORASP1       \#19       3     39142562           Cpd Het           Missense           A127V                  0.004306                      0.0037               rs61743223       Up[\*\*\*](#t2-fn1){ref-type="fn"}
  GTF3C2        \#20       2     27558834         Homozygous          Missense           L473V                  0.002537                      0.0005              rs148867164        Down[\*](#t2-fn1){ref-type="fn"}
  HENMT1        \#13       1     109193733        Homozygous          Missense           E166A                  0.000461                      0.0009              rs144705350        Up[\*\*](#t2-fn1){ref-type="fn"}
  KIAA1755      \#12      20     36848055         Homozygous          Missense           R845C                  0.000384                        NR                rs144671254         Up[\*](#t2-fn1){ref-type="fn"}
  LBP           \#14      20     36978016           Cpd Het           Missense           G64R                      NR                           NR                     NR                           ND
  LBP           \#14      20     36979309           Cpd Het           Missense           V112D                  0.000538                      0.0005              rs138570528                       ND
  MYO3B         \#42       2     171356232          Cpd Het           Missense          Q1067R                  0.000248                      0.0005              rs200292179                       ND
  MYO3B         \#42       2     171400401          Cpd Het          Splice site         None                      NR                           NR                     NR                           ND
  RAB25         \#20       1     156035717        Homozygous          Missense           E20G                   0.005891                       0.01                rs61751627     Down[\*\*\*\*](#t2-fn1){ref-type="fn"}
  SERPINA10     \#15      14     94750486           Cpd Het           Missense           Q384R                  0.008304                      0.0037               rs2232710         Down[\*](#t2-fn1){ref-type="fn"}
  SERPINA10     \#15      14     94756669           Cpd Het           Nonsense           R88X                   0.005305                      0.0032               rs2232698         Down[\*](#t2-fn1){ref-type="fn"}
  SPTB          \#11      14     65253667           Cpd Het           Missense          A1006T                  0.001153                        NR                rs151112486                       ND
  SPTB          \#11      14     65267517           Cpd Het           Missense           S278F                     NR                           NR                     NR                           ND
  TAF1L         \#39       9     32631781         Homozygous          Missense          P1266R                  0.002076                        NR                rs140558556                       NR
  TF            \#30       3     133496032        Homozygous          Missense           G671E                  0.003691                      0.0032              rs121918677      Up[\*\*\*\*](#t2-fn1){ref-type="fn"}
  THSD7B        \#22       2     138373831        Homozygous          Missense          Q1141H                  0.004745                      0.0009              rs150657202                       ND
  USH2A         \#05       1     215844468          Cpd Het           Missense          P4660L                     NR                           NR                     NR                           ND
  USH2A         \#05       1     216420214          Cpd Het           Missense           S841Y                  0.005305                      0.0027              rs111033282                       ND
  WDR6          \#36       3     49049385           Cpd Het           Missense           L140V                     NR                           NR                     NR                           ND
  WDR6          \#36       3     49050499           Cpd Het           Missense           R460H                  0.000846                      0.0009              rs142520902                       ND

The minor allele frequencies from the NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project (1KG) projects and the dbSNP137 rsID are provided. Differential expression of each gene in the spinal cord compared to non-central nervous system tissue from[@b11] is noted. Cpd Het: compound heterozygous. ND: no difference, NR: not reported,\*: p \< 10^−2^, \*\*: p \< 10^−4^, \*\*\*: p \< 10^−6^, \*\*\*\*: p \< 10^−10^.

###### Rare coding *de novo* variants in ALS trio patients

  Gene       Trio ID   Chrom   Position             Impact             Amino acid change   Minor allele frequency in ESP   Minor allele frequency in 1KG   dbSNP137 ID   Novel   Spinal cord differential expression
  --------- --------- ------- ----------- --------------------------- ------------------- ------------------------------- ------------------------------- ------------- ------- --------------------------------------
  AKD1        \#08       6     109894726           Missense                  E755K                      NR                              NR                     NR         Yes      Up[\*\*](#t3-fn1){ref-type="fn"}
  ANAPC7      \#21      12     110819574           Missense                  R108H                      NR                              NR                     NR         Yes     Down[\*\*](#t3-fn1){ref-type="fn"}
  CHRM1       \#41      11     62678572    Missense, initiator codon          M1V                       NR                              NR                     NR         Yes      Down[\*](#t3-fn1){ref-type="fn"}
  FOXN3       \#30      14     89656737            Nonsense                  Q119X                      NR                              NR                     NR         Yes      Down[\*](#t3-fn1){ref-type="fn"}
  GTF2H4      \#35       6     30880156            Missense                  R337Q                   0.010308                          0.01                 rs3218820     No                      NR
  ITPR2       \#42      12     26808680            Missense                  F850L                      NR                              NR                     NR         Yes    Up[\*\*\*\*](#t3-fn1){ref-type="fn"}
  LIMD1       \#02       3     45637047            Missense                  P226S                      NR                              NR                     NR         Yes     Down[\*\*](#t3-fn1){ref-type="fn"}
  METTL22     \#30      16      8738455            Missense                  A295V                      NR                              NR                     NR         Yes     Down[\*\*](#t3-fn1){ref-type="fn"}
  MLL3        \#02       7     151849993           Missense                  R234Q                      NR                              NR                     NR         Yes      Down[\*](#t3-fn1){ref-type="fn"}
  NLRC5       \#43      16     57073761      Missense, splice site           R256M                      NR                              NR                     NR         Yes     Down[\*\*](#t3-fn1){ref-type="fn"}
  PLA2G4C     \#24      19     48607867            Missense                  A79S                       NR                              NR                 rs13895674     No      Up[\*\*\*](#t3-fn1){ref-type="fn"}
  PSMB7       \#08       9     127119118           Missense                  I216T                      NR                              NR                     NR         Yes    Down[\*\*\*](#t3-fn1){ref-type="fn"}
  RINL        \#10      19     39359972            Missense                  R404Q                      NR                              NR                     NR         Yes                     NR
  SND1        \#24       7     127341354           Missense                  S179L                      NR                              NR                 rs24667910     No                      ND
  STK36       \#14       2     219538460           Missense                  M12R                       NR                              NR                     NR         Yes      Down[\*](#t3-fn1){ref-type="fn"}
  SV2A        \#20       1     149885128           Missense                  E89K                       NR                              NR                     NR         Yes    Up[\*\*\*\*](#t3-fn1){ref-type="fn"}
  TRRAP       \#35       7     98553842            Missense                 S1977N                      NR                              NR                     NR         Yes                     ND

The minor allele frequencies from the NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project (1 KG) projects and the dbSNP137 rsID are provided. Differential expression of each gene in the spinal cord compared to non-central nervous system tissue from[@b11] is noted. ND: no difference, NR: not reported,\*: p \< 10^−2^, \*\*: p \< 10^−4^, \*\*\*: p \< 10^−6^, \*\*\*\*: p \< 10^−10^.
